Clinical Trial Update: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Abelacimab to Apixaban for cancer-associated venous thromboembolism has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)
• abeLacimab (abeLacimab)

Snippet

Sponsor: Anthos Therapeutics, Inc. | Conditions: Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Status: TERMINATED